JP6290918B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP6290918B2
JP6290918B2 JP2015545783A JP2015545783A JP6290918B2 JP 6290918 B2 JP6290918 B2 JP 6290918B2 JP 2015545783 A JP2015545783 A JP 2015545783A JP 2015545783 A JP2015545783 A JP 2015545783A JP 6290918 B2 JP6290918 B2 JP 6290918B2
Authority
JP
Japan
Prior art keywords
seq
toxin
fragment
repeat
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502551A (ja
JP2016502551A5 (enExample
Inventor
ボウトリュー，ドミニク
マリー ジェーン バレンタイン ジャーメイン，ソフィー
マリー ジェーン バレンタイン ジャーメイン，ソフィー
ウォールマック，ヒューグース
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2016502551A publication Critical patent/JP2016502551A/ja
Publication of JP2016502551A5 publication Critical patent/JP2016502551A5/ja
Application granted granted Critical
Publication of JP6290918B2 publication Critical patent/JP6290918B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015545783A 2012-12-05 2013-12-03 免疫原性組成物 Active JP6290918B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1221875.6 2012-12-05
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018020900A Division JP6626521B2 (ja) 2012-12-05 2018-02-08 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2016502551A JP2016502551A (ja) 2016-01-28
JP2016502551A5 JP2016502551A5 (enExample) 2017-01-19
JP6290918B2 true JP6290918B2 (ja) 2018-03-07

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545783A Active JP6290918B2 (ja) 2012-12-05 2013-12-03 免疫原性組成物
JP2018020900A Active JP6626521B2 (ja) 2012-12-05 2018-02-08 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018020900A Active JP6626521B2 (ja) 2012-12-05 2018-02-08 免疫原性組成物

Country Status (22)

Country Link
US (2) US9694064B2 (enExample)
EP (2) EP2928489B1 (enExample)
JP (2) JP6290918B2 (enExample)
CN (2) CN112807422A (enExample)
AR (1) AR093712A1 (enExample)
AU (1) AU2013354186A1 (enExample)
BR (1) BR112015012841B1 (enExample)
CA (1) CA2893435C (enExample)
CY (1) CY1121560T1 (enExample)
DK (2) DK3513806T5 (enExample)
ES (2) ES2939307T3 (enExample)
FI (1) FI3513806T3 (enExample)
HR (2) HRP20230359T1 (enExample)
HU (2) HUE061273T2 (enExample)
LT (2) LT3513806T (enExample)
PL (2) PL3513806T3 (enExample)
PT (2) PT2928489T (enExample)
SG (1) SG11201503861UA (enExample)
SI (2) SI2928489T1 (enExample)
TR (1) TR201905272T4 (enExample)
WO (1) WO2014086787A1 (enExample)
ZA (1) ZA201503927B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543907A (ja) * 2005-06-27 2008-12-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
SI3505531T1 (sl) 2011-04-22 2024-02-29 Wyeth Llc Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013354186A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP3160500B1 (en) * 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
CA2954087C (en) * 2014-07-25 2023-09-19 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
CA2976976C (en) 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109311950A (zh) 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201908376UA (en) 2017-03-15 2019-10-30 Novavax Inc Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
CA3141165A1 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Vaccine compositions for clostridium difficile
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN120475988A (zh) * 2022-12-13 2025-08-12 辉瑞公司 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1041149B8 (en) 1994-10-24 2007-10-03 Allergan, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2000061762A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
DK2086582T3 (da) * 2006-10-12 2013-02-04 Glaxosmithkline Biolog Sa Vaccine omfattende en olie-i-vand-emulsionsadjuvans
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
BRPI0816790A8 (pt) 2007-09-14 2017-05-16 Sanofi Pasteur Biologics Co Composições farmacêuticas contendo toxóides a e b de clostridium difficile
CN102099052A (zh) * 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
CN103732750A (zh) 2011-05-27 2014-04-16 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
AU2013354186A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition

Also Published As

Publication number Publication date
FI3513806T3 (fi) 2023-04-26
HUE061273T2 (hu) 2023-06-28
SG11201503861UA (en) 2015-06-29
JP2018104446A (ja) 2018-07-05
ES2721930T3 (es) 2019-08-06
ES2939307T3 (es) 2023-04-20
CN112807422A (zh) 2021-05-18
PL3513806T3 (pl) 2023-05-15
AR093712A1 (es) 2015-06-17
CN104884081A (zh) 2015-09-02
BR112015012841A2 (pt) 2017-09-26
US9694064B2 (en) 2017-07-04
DK3513806T5 (da) 2024-09-02
CA2893435C (en) 2024-11-12
US20170340719A1 (en) 2017-11-30
TR201905272T4 (tr) 2019-05-21
EP3513806A1 (en) 2019-07-24
DK2928489T3 (en) 2019-04-23
EP2928489A1 (en) 2015-10-14
HUE043091T2 (hu) 2019-08-28
JP2016502551A (ja) 2016-01-28
PL2928489T3 (pl) 2019-07-31
EP2928489B1 (en) 2019-02-27
ZA201503927B (en) 2017-11-29
JP6626521B2 (ja) 2019-12-25
EP3513806B1 (en) 2023-01-25
AU2013354186A1 (en) 2014-06-12
SI3513806T1 (sl) 2023-04-28
SI2928489T1 (sl) 2019-05-31
PT2928489T (pt) 2019-05-28
LT3513806T (lt) 2023-04-11
HRP20230359T1 (hr) 2023-06-09
DK3513806T3 (da) 2023-02-27
US10130694B2 (en) 2018-11-20
CY1121560T1 (el) 2020-05-29
LT2928489T (lt) 2019-04-10
WO2014086787A1 (en) 2014-06-12
CA2893435A1 (en) 2014-06-12
BR112015012841B1 (pt) 2022-05-03
PT3513806T (pt) 2023-03-02
HRP20190711T1 (hr) 2019-05-31
US20150313984A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
JP6626521B2 (ja) 免疫原性組成物
EP2707393B1 (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
US10377816B2 (en) Nucleotide sequences, vectors and host cells
JP2020100625A (ja) クロストリジウム・ディフィシル免疫原性組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180208

R150 Certificate of patent or registration of utility model

Ref document number: 6290918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250